Clariscan 0,5 mmol/ml Injektionsvätska, lösning

国家: 瑞典

语言: 瑞典文

来源: Läkemedelsverket (Medical Products Agency)

有效成分:

gadoterinsyra

可用日期:

GE Healthcare AS

ATC代码:

V08CA02

INN（国际名称）:

gadoteric acid

剂量:

0,5 mmol/ml

药物剂型:

Injektionsvätska, lösning

组成:

gadoterinsyra 279,32 mg Aktiv substans

处方类型:

Receptbelagt

產品總結:

Förpacknings: Injektionsflaska, 5 ml; Injektionsflaska, 10 ml; Injektionsflaska, 15 ml; Injektionsflaska, 20 ml; Injektionsflaska, 10 x 5 ml; Injektionsflaska, 10 x 10 ml; Injektionsflaska, 10 x 15 ml; Injektionsflaska, 10 x 20 ml; Flaska, 50 ml (glas); Flaska, 10 x 50 ml (glas); Flaska, 100 ml (glas); Flaska, 10 x 100 ml (glas); Flaska, 50 ml (plast); Flaska, 100 ml (plast); Flaska, 10 x 50 ml (plast); Flaska, 10 x 100 ml (plast)

授权状态:

Godkänd

授权日期:

2017-02-20

资料单张

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLARISCAN 0.5 MMOL/MLSOLUTION FOR INJECTION
CLARISCAN 0.5 MMOL/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
GADOTERIC ACID
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
● Keep this leaflet. You may need to read it again.
● If you have any further questions, ask your doctor or radiologist
or pharmacist.
● If you get any of the side effects, talk to your doctor,
radiologist or pharmacist. This includes any
possible side effects not listed in this leaflet. See section 4.
IN THIS LEAFLET
:
1. What Clariscan is and what it is used for
2. What you need to know before you are given Clariscan
3. How you will be given Clariscan
4. Possible side effects
5. How to store Clariscan
6. Contents of the pack and other information
1. WHAT CLARISCAN IS AND WHAT IT IS USED FOR
WHAT CLARISCAN IS
Clariscan contains the active substance gadoteric acid. It belongs to
a group called “contrast agents”
used for magnetic resonance imaging” (MRI).
WHAT CLARISCAN IS USED FOR
Clariscan is used to enhance the contrast of the images obtained
during MRI examinations.
In adults and in children and adolescents 0-18 years old:
- MRI of the CNS including of defects (lesions) in brain, spine, and
surrounding tissues
In adults and in children and adolescents 6 months – 18 years old:
- Whole body MRI including defects (lesions)
In adults only:
- MR angiography including defects (lesions) or narrowing (stenosis)
in arteries, except in coronary
arteries.
This medicine is for diagnostic use only
HOW CLARISCAN WORKS
Clariscan makes the pictures on an MRI scanner easier to see. It does
this by increasing the contrast
between the part of the body being looked at and the rest of the body.
This allows doctors or
radiologists to see different areas of the body better.
2
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN CLARISCAN
YOU SHOULD NOT BE GIVEN CLARISCAN :
•
if you are allergic to gadoteric acid or any of the other ingr

产品特点

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Clariscan 0.5 mmol/ mL solution for injection
Clariscan 0.5 mmol/ mL solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 mL solution for injection contains 279.32 mg gadoteric acid*(as
gadoterate meglumine) equivalent to 0.5
mmol
Tetraxetan (DOTA)
202.46 mg
Gadolinium oxide
90.62 mg
* Gadoteric acid: gadolinium complex with1,4,7,10
tetraazacyclododecane N,N’,N”,N’’’ tetraacetic acid
(tetraxetan (DOTA))
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
Solution for injection in prefilled syringe
Clear, colourless to slightly yellow solution
Contrast medium concentration
279.32 mg/mL
equivalent to 0.5 mmol/mL
Osmolality at 37 °C
1350 mOsm.kg
-1
Viscosity at 20 °C
3.0 mPa.s
Viscosity at 37 °C
2.1 mPa.s
pH value
6.5 – 8.0
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
This medicinal product is for diagnostic use only.
Clariscan should be used only when diagnostic information is essential
and not available with unenhanced
magnetic resonance imaging (MRI).
Clariscan is a contrast agent indicated for enhancement of the
contrast in Magnetic Resonance Imaging for
a better visualization/delineation.
Adult population and paediatric population (0-18 years):
- lesions of the brain, spine, and surrounding tissues
- whole body MRI (see section 4.2)
Use for whole body is not recommended in children less than 6 months
In adults only:
- lesions or stenoses of the non-coronary arteries (MR Angiography).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
This medicinal product should only be administered by trained
healthcare professionals with technical
expertise in performing and interpreting gadolinium enhanced MRI.
Posology
The lowest dose that provides sufficient enhancement for diagnostic
purposes should be used. The dose
should be calculated based on the patient’s body weight, and should
not exceed the recommended dose per
kilogram of body weight detailed in this